The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Oral decitabine/cedazuridine with venetoclax and gilteritinib in patients with AML
Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of oral decitabine/cedazuridine with venetoclax and gilteritinib in relapsed/refractory and newly diagnosed acute myeloid leukemia (AML). The data indicate that this combination is well-tolerated and shows promising efficacy, offering a more comfortable administration option for potential use in clinical practice. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
